Market Cap 1.47B
Revenue (ttm) 43.27M
Net Income (ttm) -130.87M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -302.45%
Debt to Equity Ratio 0.00
Volume 1,429,818
Avg Vol 1,347,702
Day's Range N/A - N/A
Shares Out 82.79M
Stochastic %K 98%
Beta 1.67
Analysts Strong Sell
Price Target $34.00

Company Profile

EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Duras...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 926 5000
Address:
480 Pleasant Street, Suite C-400, Watertown, United States
KimboIce
KimboIce May. 11 at 8:25 PM
0 · Reply
Poet5
Poet5 May. 11 at 3:33 PM
$EYPT Watch for a secondary offering after close of today, hence the high volune.
1 · Reply
KimboIce
KimboIce May. 11 at 2:44 PM
$EYPT the run up starts today
0 · Reply
Quantumup
Quantumup May. 8 at 7:24 PM
BofA reiterated Top Pick $OCUL Buy; $27 in its SMID cap investor's guide to Health Care (including top stock ideas) $EYPT REGN FDMT RHHBY KOD $SRZN Here's what BofA said in its note: https://x.com/Quantumup1/status/2052831264231526811?s=20
0 · Reply
Quantumup
Quantumup May. 7 at 12:36 PM
Guggenheim reiterated its Top Pick $EYPT Buy; $68 $OCUL $SRZN REGN RHHBY FDMT KOD Here's what Guggenheim had to say in its note to investors: https://x.com/Quantumup1/status/2052365956958109965?s=20
1 · Reply
brucino
brucino May. 7 at 11:37 AM
$EYPT It's only being kept alive because of optimistic expectations about the trials, because if you look at the budget, there's a lot to worry about... But we'll have to see what price level we'll be at when the clinical data are released. Good luck to us 🤞🤞💪💪
1 · Reply
Jjarnold44
Jjarnold44 May. 6 at 7:26 PM
$EYPT Didn't one of you beat me up saying you would need to raise this year? Welp, here ya go!
1 · Reply
Poet5
Poet5 May. 6 at 6:44 PM
$EYPT Yeah! let ot sink to 10-12 range. what bullshit!
1 · Reply
SuperGreenToday
SuperGreenToday May. 6 at 1:47 PM
$EYPT Share Price: $13.77 Contract Selected: Aug 21, 2026 $15 Calls Buy Zone: $3.21 – $3.97 Target Zone: $5.16 – $6.30 Potential Upside: 52% ROI Time to Expiration: 106 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
brucino
brucino May. 6 at 11:17 AM
$EYPT today will be a disaster😡😡
2 · Reply
Latest News on EYPT
EyePoint reports Q1 EPS (99c), consensus (81c)

2026-05-07T07:35:29.000Z - 6 days ago

EyePoint reports Q1 EPS (99c), consensus (81c)


EyePoint Earnings Call Transcript: Q1 2026

May 6, 2026, 8:30 AM EDT - 7 days ago

EyePoint Earnings Call Transcript: Q1 2026


EyePoint reports inducement grants under NASDAQ listing rule

2026-03-16T11:16:50.000Z - 2 months ago

EyePoint reports inducement grants under NASDAQ listing rule


EyePoint price target raised to $35 from $31 at Citi

2026-03-09T10:55:47.000Z - 2 months ago

EyePoint price target raised to $35 from $31 at Citi


EyePoint price target raised to $30 from $23 at H.C. Wainwright

2026-03-05T11:11:09.000Z - 2 months ago

EyePoint price target raised to $30 from $23 at H.C. Wainwright


EyePoint price target raised to $29 from $27 at Chardan

2026-03-04T19:55:31.000Z - 2 months ago

EyePoint price target raised to $29 from $27 at Chardan


EyePoint Earnings Call Transcript: Q4 2025

Mar 4, 2026, 8:30 AM EST - 2 months ago

EyePoint Earnings Call Transcript: Q4 2025


EyePoint reports Q4 EPS (81c), consensus (75c)

2026-03-04T12:10:17.000Z - 2 months ago

EyePoint reports Q4 EPS (81c), consensus (75c)


EyePoint expects cash to fund operations into Q4 2027

2026-03-04T12:09:56.000Z - 2 months ago

EyePoint expects cash to fund operations into Q4 2027


EyePoint price target raised to $36 from $33 at Mizuho

2026-02-19T12:28:49.000Z - 2 months ago

EyePoint price target raised to $36 from $33 at Mizuho


EyePoint appoints Campbell as Chief Commercial Officer

2026-02-18T12:05:24.000Z - 3 months ago

EyePoint appoints Campbell as Chief Commercial Officer


EyePoint Appoints Michael Campbell as Chief Commercial Officer

Feb 18, 2026, 7:00 AM EST - 3 months ago

EyePoint Appoints Michael Campbell as Chief Commercial Officer


EyePoint reports inducement grants under NASDAQ listing rule

2026-02-17T12:10:23.000Z - 3 months ago

EyePoint reports inducement grants under NASDAQ listing rule


EyePoint reports inducement grants under NASDAQ listing rule

2026-01-16T12:06:17.000Z - 4 months ago

EyePoint reports inducement grants under NASDAQ listing rule


EyePoint Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 10:30 AM EST - 4 months ago

EyePoint Transcript: 44th Annual J.P. Morgan Healthcare Conference


EyePoint reports inducement grants under NASDAQ listing rule

2025-12-16T12:11:01.000Z - 5 months ago

EyePoint reports inducement grants under NASDAQ listing rule


EyePoint reports inducement grants under NASDAQ listing rule

2025-11-17T12:10:54.000Z - 6 months ago

EyePoint reports inducement grants under NASDAQ listing rule


EyePoint Transcript: Stifel 2025 Healthcare Conference

Nov 12, 2025, 10:40 AM EST - 6 months ago

EyePoint Transcript: Stifel 2025 Healthcare Conference


EyePoint selloff brings buying opportunity, says Mizuho

2025-11-11T12:20:18.000Z - 6 months ago

EyePoint selloff brings buying opportunity, says Mizuho


EyePoint Earnings Call Transcript: Q3 2025

Nov 5, 2025, 8:30 AM EST - 6 months ago

EyePoint Earnings Call Transcript: Q3 2025


EyePoint reports Q3 EPS (85c), consensus (77c)

2025-11-05T12:11:53.000Z - 6 months ago

EyePoint reports Q3 EPS (85c), consensus (77c)


EyePoint expects cash to fund operations into Q4 of 2027

2025-11-05T12:11:34.000Z - 6 months ago

EyePoint expects cash to fund operations into Q4 of 2027


EyePoint Announces Pricing of Public Offering

Oct 14, 2025, 10:43 PM EDT - 7 months ago

EyePoint Announces Pricing of Public Offering


EyePoint Announces Proposed Public Offering of Common Stock

Oct 14, 2025, 4:35 PM EDT - 7 months ago

EyePoint Announces Proposed Public Offering of Common Stock


EyePoint Transcript: Cantor Global Healthcare Conference 2025

Sep 3, 2025, 2:45 PM EDT - 8 months ago

EyePoint Transcript: Cantor Global Healthcare Conference 2025


EyePoint Transcript: Citi's Biopharma Back to School Conference

Sep 2, 2025, 2:30 PM EDT - 9 months ago

EyePoint Transcript: Citi's Biopharma Back to School Conference


EyePoint Earnings Call Transcript: Q2 2025

Aug 6, 2025, 8:30 AM EDT - 10 months ago

EyePoint Earnings Call Transcript: Q2 2025


EyePoint Transcript: Stifel 2025 Virtual Ophthalmology Forum

May 27, 2025, 8:30 AM EDT - 1 year ago

EyePoint Transcript: Stifel 2025 Virtual Ophthalmology Forum


EyePoint Earnings Call Transcript: Q1 2025

May 7, 2025, 8:30 AM EDT - 1 year ago

EyePoint Earnings Call Transcript: Q1 2025


EyePoint Earnings Call Transcript: Q4 2024

Mar 5, 2025, 8:30 AM EST - 1 year ago

EyePoint Earnings Call Transcript: Q4 2024


EyePoint Transcript: Guggenheim SMID Cap Biotech Conference

Feb 6, 2025, 9:30 AM EST - 1 year ago

EyePoint Transcript: Guggenheim SMID Cap Biotech Conference


EyePoint Transcript: Status Update

Feb 5, 2025, 8:00 AM EST - 1 year ago

EyePoint Transcript: Status Update


EyePoint to Present at Guggenheim SMID Cap Biotech Conference

Jan 30, 2025, 7:00 AM EST - 1 year ago

EyePoint to Present at Guggenheim SMID Cap Biotech Conference


EyePoint Transcript: UBS Global Healthcare Conference 2024

Nov 13, 2024, 4:15 PM EST - 1 year ago

EyePoint Transcript: UBS Global Healthcare Conference 2024


EyePoint Transcript: UBS Virtual Ophthalmology Day

Oct 2, 2024, 2:30 PM EDT - 1 year ago

EyePoint Transcript: UBS Virtual Ophthalmology Day


EyePoint Transcript: R&D Day 2024

Jun 26, 2024, 8:00 AM EDT - 2 years ago

EyePoint Transcript: R&D Day 2024


EyePoint Pharmaceuticals to Host R&D Day on June 26, 2024

Jun 18, 2024, 7:00 AM EDT - 2 years ago

EyePoint Pharmaceuticals to Host R&D Day on June 26, 2024


EyePoint Transcript: Study Update

May 6, 2024, 8:00 AM EDT - 2 years ago

EyePoint Transcript: Study Update


EyePoint Earnings Call Transcript: Q4 2023

Mar 7, 2024, 8:30 AM EST - 2 years ago

EyePoint Earnings Call Transcript: Q4 2023


KimboIce
KimboIce May. 11 at 8:25 PM
0 · Reply
Poet5
Poet5 May. 11 at 3:33 PM
$EYPT Watch for a secondary offering after close of today, hence the high volune.
1 · Reply
KimboIce
KimboIce May. 11 at 2:44 PM
$EYPT the run up starts today
0 · Reply
Quantumup
Quantumup May. 8 at 7:24 PM
BofA reiterated Top Pick $OCUL Buy; $27 in its SMID cap investor's guide to Health Care (including top stock ideas) $EYPT REGN FDMT RHHBY KOD $SRZN Here's what BofA said in its note: https://x.com/Quantumup1/status/2052831264231526811?s=20
0 · Reply
Quantumup
Quantumup May. 7 at 12:36 PM
Guggenheim reiterated its Top Pick $EYPT Buy; $68 $OCUL $SRZN REGN RHHBY FDMT KOD Here's what Guggenheim had to say in its note to investors: https://x.com/Quantumup1/status/2052365956958109965?s=20
1 · Reply
brucino
brucino May. 7 at 11:37 AM
$EYPT It's only being kept alive because of optimistic expectations about the trials, because if you look at the budget, there's a lot to worry about... But we'll have to see what price level we'll be at when the clinical data are released. Good luck to us 🤞🤞💪💪
1 · Reply
Jjarnold44
Jjarnold44 May. 6 at 7:26 PM
$EYPT Didn't one of you beat me up saying you would need to raise this year? Welp, here ya go!
1 · Reply
Poet5
Poet5 May. 6 at 6:44 PM
$EYPT Yeah! let ot sink to 10-12 range. what bullshit!
1 · Reply
SuperGreenToday
SuperGreenToday May. 6 at 1:47 PM
$EYPT Share Price: $13.77 Contract Selected: Aug 21, 2026 $15 Calls Buy Zone: $3.21 – $3.97 Target Zone: $5.16 – $6.30 Potential Upside: 52% ROI Time to Expiration: 106 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
brucino
brucino May. 6 at 11:17 AM
$EYPT today will be a disaster😡😡
2 · Reply
StocktwitsEarnings
StocktwitsEarnings May. 6 at 11:14 AM
$EYPT Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.99 down -52.31% YoY • Reported revenue of $0.7M down -97.15% YoY • EyePoint expects its cash, cash equivalents, and marketable securities of $223M as of March 31, 2026, will fund operations into Q4 2027, extending beyond key Phase 3 wet AMD program milestones.
0 · Reply
brucino
brucino May. 6 at 10:50 AM
$EYPT they are few volumes, but it's not like we're starting off well....-8%
1 · Reply
brucino
brucino May. 5 at 10:18 AM
$EYPT Quarterly report tomorrow...what do you think? They'll also say something about how the trials are progressing.
1 · Reply
rizzato
rizzato Apr. 29 at 6:04 PM
$EYPT did they finish the gasoline???????????????
1 · Reply
rizzato
rizzato Apr. 29 at 6:03 PM
$EYPT what is going on today?
0 · Reply
brucino
brucino Apr. 28 at 2:06 PM
$CXAI $GPRO $EYPT $DOMH $AYTU hot !!!💣🚀💥💰💰
0 · Reply
twib
twib Apr. 27 at 3:34 PM
$EYPT Creeping up is better than ....
0 · Reply
Love_To_Learn
Love_To_Learn Apr. 27 at 1:18 PM
$EYPT BEEN ACCUMULATING YOU LATELY
0 · Reply
Quantumup
Quantumup Apr. 21 at 12:21 PM
TD Cowen🏁 $SRZN at a Buy rating. $OCUL $EYPT MRK REGN RHHBY FDMT KOD TD Cowen said in its initiation report: Surrozen is developing multifunctional antibodies that leverage Wnt activation for vascular retinopathies. Leadi candidate SZN-8141 combines Wnt agonism with VEGF antagonism and an IND is expected in H2:26. We estimate SZN-8141 addresses a $5B+ opportunity in wAMD and DME. We expect SRZN to create much L-T shareholder value as its pipeline advances. We are initiating with a Buy rating.
0 · Reply
brucino
brucino Apr. 20 at 6:59 AM
$GPRO 💣🚀🛰️ ticker of the day $GPRO $DOMH $EYPT $AYTU $CXAI Let'go !!!!💣🚀
0 · Reply
BioTechHealthX
BioTechHealthX Apr. 19 at 2:41 AM
$EYPT EyePoint Pharmaceuticals (EYPT) is transforming ophthalmology with sustained-release drug delivery technology designed for better patient outcomes. Here’s why this rising biotech stock is gaining momentum fast. https://biotechhealthx.com/biotech-news/heres-what-makes-eyepoint-pharmaceuticals-eypt-a-great-investment-pick/
0 · Reply
brucino
brucino Apr. 17 at 6:21 PM
$EYPT Road to 20$ >>>>>
2 · Reply